Most Read Articles
01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
16 Mar 2017
Probiotics have a long history of use in humans. Defined as "live organisms that confer a health benefit on the host when administered in adequate amounts", the spectrum of use of probiotics in humans ranges from foods and dietary supplements to pharmaceutical/nutraceutical products to affect general health and disease. While the genera Lactobacillus and Bifidobacterium are the two most common probiotics associated with consumer products, there exist other organisms (eg, the yeast Saccharomyces cerevisiae, some non-pathogenic strains of Escherichia coli and Bacillus species) that are used as probiotics.1–3 One of them is the probiotic strain B. clausii that has been found to be effective for the treatment of diarrhoea and antibiotic-associated gastrointestinal side effects.4–6
Stephen Padilla, 06 Dec 2016
Dengvaxia, a recombinant, live-attenuated dengue vaccine, has the potential to bring down the number of hospitalizations by 13 to 25 percent and be cost-effective in areas of moderate-to-high dengue endemicity, according to a model comparison study.
06 Nov 2017
Treatment with rifaximin appears to effectively prevent spontaneous bacterial peritonitis in patients with cirrhosis and ascites compared with systemically absorbed antibiotics and placebo, a study has found.

Correct use of anti-malarials to counter Plasmodium falciparum resistance

19 Aug 2016

The rise of anti-malarial resistant Plasmodium falciparum in areas where malaria is endemic, such as Southeast Asia, calls for the safe and right use of current antimalarials.

In P. falciparum, resistance had been observed in all currently used antimalarials, which includes chloroquine, amodiaquine, mefloquine, quinine and sulfadoxine-pyrimethamine. As such, the WHO guidelines now recommend the use of artemisinin-based combination therapies (ACT) instead. However, recent years has seen an increase in P. falciparum resistance to ACT. This is a problem that needs to be addressed quickly as there is a limited number of antimalarials available. To put a stop to the rise in resistance, doctors can play a role by ensuring proper prescription of antimalarials. Proper prescription includes the right medication, dose and duration of treatment. At the same time, patients have to play their part in being compliant. [WHO. Guidelines for the treatment of malaria. Third edition. Available at: www.who.int/malaria/publications/atoz/9789241549127/en/ Accessed on 16 Dec]

Local guideline recommend the use of ACT for 3 days to treat uncomplicated P. falciparum infections. An alternative is to prescribe oral quinine plus oral doxycycline for 7 days. It is important to note that monotherapy is not recommended for the treatment of malaria as it will lead to increased plasmodium resistance. In severe P. falciparum infections, artesunate should be given together with doxycycline. The alternative is to prescribe quinine plus doxycycline. [MOH. Management guidelines of malaria in Malaysia. Available at: www.moh.gov.my/index.php/pages/view/118 Accessed on 16 Dec]

In locations where P. falciparum is resistant to commonly used antimalarials, the combination of quinine and doxycycline has been shown to be effective and well-tolerated. [Malar J 2015;14:445] Despite not being recommended for younger children and pregnant women, there are rarely any severe adverse effects reported in the two groups when treated with doxycycline. Another advantage of this medication is there is rarely any resistance to it. In cases of treatment failures with doxycycline, the cause has been linked to inadequate doses and poor patient compliance. Besides being an effective treatment for malaria when used in combination with other antimalarials, doxycycline is also an effective chemoprophylaxis that kills the malaria parasite in its erythrocytic stage.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Aug 2017
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
16 Mar 2017
Probiotics have a long history of use in humans. Defined as "live organisms that confer a health benefit on the host when administered in adequate amounts", the spectrum of use of probiotics in humans ranges from foods and dietary supplements to pharmaceutical/nutraceutical products to affect general health and disease. While the genera Lactobacillus and Bifidobacterium are the two most common probiotics associated with consumer products, there exist other organisms (eg, the yeast Saccharomyces cerevisiae, some non-pathogenic strains of Escherichia coli and Bacillus species) that are used as probiotics.1–3 One of them is the probiotic strain B. clausii that has been found to be effective for the treatment of diarrhoea and antibiotic-associated gastrointestinal side effects.4–6
Stephen Padilla, 06 Dec 2016
Dengvaxia, a recombinant, live-attenuated dengue vaccine, has the potential to bring down the number of hospitalizations by 13 to 25 percent and be cost-effective in areas of moderate-to-high dengue endemicity, according to a model comparison study.
06 Nov 2017
Treatment with rifaximin appears to effectively prevent spontaneous bacterial peritonitis in patients with cirrhosis and ascites compared with systemically absorbed antibiotics and placebo, a study has found.